Suppr超能文献

RBM39-U2AF65剪接因子复合物中的UHM-ULM相互作用。

UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex.

作者信息

Stepanyuk Galina A, Serrano Pedro, Peralta Eigen, Farr Carol L, Axelrod Herbert L, Geralt Michael, Das Debanu, Chiu Hsiu-Ju, Jaroszewski Lukasz, Deacon Ashley M, Lesley Scott A, Elsliger Marc-André, Godzik Adam, Wilson Ian A, Wüthrich Kurt, Salomon Daniel R, Williamson James R

机构信息

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.

出版信息

Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):497-511. doi: 10.1107/S2059798316001248. Epub 2016 Mar 24.

Abstract

RNA-binding protein 39 (RBM39) is a splicing factor and a transcriptional co-activator of estrogen receptors and Jun/AP-1, and its function has been associated with malignant progression in a number of cancers. The C-terminal RRM domain of RBM39 belongs to the U2AF homology motif family (UHM), which mediate protein-protein interactions through a short tryptophan-containing peptide known as the UHM-ligand motif (ULM). Here, crystal and solution NMR structures of the RBM39-UHM domain, and the crystal structure of its complex with U2AF65-ULM, are reported. The RBM39-U2AF65 interaction was confirmed by co-immunoprecipitation from human cell extracts, by isothermal titration calorimetry and by NMR chemical shift perturbation experiments with the purified proteins. When compared with related complexes, such as U2AF35-U2AF65 and RBM39-SF3b155, the RBM39-UHM-U2AF65-ULM complex reveals both common and discriminating recognition elements in the UHM-ULM binding interface, providing a rationale for the known specificity of UHM-ULM interactions. This study therefore establishes a structural basis for specific UHM-ULM interactions by splicing factors such as U2AF35, U2AF65, RBM39 and SF3b155, and a platform for continued studies of intermolecular interactions governing disease-related alternative splicing in eukaryotic cells.

摘要

RNA结合蛋白39(RBM39)是一种剪接因子,也是雌激素受体以及Jun/AP-1的转录共激活因子,其功能与多种癌症的恶性进展相关。RBM39的C端RRM结构域属于U2AF同源基序家族(UHM),该家族通过一种名为UHM配体基序(ULM)的含色氨酸短肽介导蛋白质-蛋白质相互作用。本文报道了RBM39-UHM结构域的晶体结构和溶液核磁共振结构,以及它与U2AF65-ULM复合物的晶体结构。通过从人细胞提取物中进行免疫共沉淀、等温滴定量热法以及对纯化蛋白进行核磁共振化学位移扰动实验,证实了RBM39与U2AF65之间的相互作用。与相关复合物(如U2AF35-U2AF65和RBM39-SF3b155)相比,RBM39-UHM-U2AF65-ULM复合物在UHM-ULM结合界面揭示了共同的和有区别的识别元件,为已知的UHM-ULM相互作用特异性提供了理论依据。因此,本研究为U2AF35、U2AF65、RBM39和SF3b155等剪接因子特异性的UHM-ULM相互作用建立了结构基础,也为持续研究真核细胞中控制疾病相关可变剪接的分子间相互作用搭建了一个平台。

相似文献

1
UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex.
Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):497-511. doi: 10.1107/S2059798316001248. Epub 2016 Mar 24.
2
Cancer-relevant splicing factor CAPERα engages the essential splicing factor SF3b155 in a specific ternary complex.
J Biol Chem. 2014 Jun 20;289(25):17325-37. doi: 10.1074/jbc.M114.558825. Epub 2014 May 2.
3
Dimerization and protein binding specificity of the U2AF homology motif of the splicing factor Puf60.
J Biol Chem. 2009 Jan 2;284(1):630-639. doi: 10.1074/jbc.M805395200. Epub 2008 Oct 29.
4
U2AF-homology motif interactions are required for alternative splicing regulation by SPF45.
Nat Struct Mol Biol. 2007 Jul;14(7):620-9. doi: 10.1038/nsmb1260. Epub 2007 Jun 24.
5
A UHM-ULM interface with unusual structural features contributes to U2AF2 and SF3B1 association for pre-mRNA splicing.
J Biol Chem. 2022 Aug;298(8):102224. doi: 10.1016/j.jbc.2022.102224. Epub 2022 Jul 1.
6
Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly.
Nat Commun. 2020 Nov 6;11(1):5621. doi: 10.1038/s41467-020-19514-1.
10
Structure, phosphorylation and U2AF65 binding of the N-terminal domain of splicing factor 1 during 3'-splice site recognition.
Nucleic Acids Res. 2013 Jan;41(2):1343-54. doi: 10.1093/nar/gks1097. Epub 2012 Nov 21.

引用本文的文献

1
RNA-coupled CRISPR Screens Reveal ZNF207 as a Regulator of LMNA Aberrant Splicing in Progeria.
bioRxiv. 2025 Apr 26:2025.04.25.648738. doi: 10.1101/2025.04.25.648738.
2
RBM39 shapes innate immunity by controlling the expression of key factors of the interferon response.
Front Immunol. 2025 Apr 22;16:1568056. doi: 10.3389/fimmu.2025.1568056. eCollection 2025.
4
Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.
Blood Adv. 2025 Apr 22;9(8):1991-2005. doi: 10.1182/bloodadvances.2025015815.
5
Challenges in Therapeutically Targeting the RNA-Recognition Motif.
Wiley Interdiscip Rev RNA. 2024 Nov-Dec;15(6):e1877. doi: 10.1002/wrna.1877.
7
Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39.
Nat Commun. 2023 Sep 4;14(1):5366. doi: 10.1038/s41467-023-40254-5.
8
Pre-mRNA splicing-associated diseases and therapies.
RNA Biol. 2023 Jan;20(1):525-538. doi: 10.1080/15476286.2023.2239601.
9
Therapeutic Targeting of RNA Splicing in Cancer.
Genes (Basel). 2023 Jun 29;14(7):1378. doi: 10.3390/genes14071378.
10
The identification of protein and RNA interactors of the splicing factor Caper in the adult nervous system.
Front Mol Neurosci. 2023 Jun 23;16:1114857. doi: 10.3389/fnmol.2023.1114857. eCollection 2023.

本文引用的文献

4
Cancer-relevant splicing factor CAPERα engages the essential splicing factor SF3b155 in a specific ternary complex.
J Biol Chem. 2014 Jun 20;289(25):17325-37. doi: 10.1074/jbc.M114.558825. Epub 2014 May 2.
5
Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis.
Tumour Biol. 2014 Jul;35(7):6311-7. doi: 10.1007/s13277-014-1819-y. Epub 2014 Mar 19.
6
CAPER, a novel regulator of human breast cancer progression.
Cell Cycle. 2014;13(8):1256-64. doi: 10.4161/cc.28156. Epub 2014 Feb 17.
7
xRRM: a new class of RRM found in the telomerase La family protein p65.
RNA Biol. 2013 Mar;10(3):353-9. doi: 10.4161/rna.23608. Epub 2013 Jan 17.
8
The J-UNIO protocol for automated protein structure determination by NMR in solution.
J Biomol NMR. 2012 Aug;53(4):341-54. doi: 10.1007/s10858-012-9645-2. Epub 2012 Jul 3.
9
CSE1L, DIDO1 and RBM39 in colorectal adenoma to carcinoma progression.
Cell Oncol (Dordr). 2012 Aug;35(4):293-300. doi: 10.1007/s13402-012-0088-2. Epub 2012 Jun 19.
10
TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression.
Gut. 2012 Nov;61(11):1568-75. doi: 10.1136/gutjnl-2011-301153. Epub 2011 Dec 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验